BrainStorm Cell Therapeutics Showcases NurOwn at NEALS Meeting
BrainStorm Cell Therapeutics Showcases NurOwn at NEALS Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a pioneering company specializing in cellular therapies for neurodegenerative disorders, is proud to share its acceptance of two pivotal abstracts for NurOwn® (MSC-NTF or Debamestrocel) at the upcoming Annual Northeastern Amyotrophic Lateral Sclerosis Consortium (NEALS) Meeting.
Focus on Innovation and Impact
During this year's NEALS meeting, BrainStorm plans to unveil the latest findings and developments concerning NurOwn. The insights and constructive feedback from the ALS community are key to their mission of addressing the critical needs of patients facing this life-altering condition. Chaim Lebovits, the President and CEO of BrainStorm, emphasizes the company's dedication to initiating a Phase 3b clinical trial aimed at affirmatively demonstrating the efficacy of NurOwn in early-stage ALS patients.
Upcoming Presentations
BrainStorm will feature two enlightening presentations during the conference:
Title: Debamestrocel Long-Term Benefits on Survival and Neurodegeneration in ALS Expanded Access Program
Lead Author: Bob Dagher, MD
Session: Poster Session 1
Date and Time: 4.30 – 6.30 PM ET, Tuesday, Oct 22
Location: Sea Salon & Sand Salon, Opal Sands Resort
Title: An Overview of The Phase 3b Clinical Trial of Debamestrocel in ALS
Lead Author: Bob Dagher, MD
Session: Poster Session 2
Date and Time: 4.00 – 6.00 PM ET, Wednesday, Oct 23
Location: Sea Salon & Sand Salon, Opal Sands Resort
Near-term Milestones
As BrainStorm prepares to showcase its results, there are anticipations of multiple significant milestones ahead that hold promise for enhancing the value of its research and developments in ALS treatments. The efforts reflect the company's long-standing commitment to providing innovative treatment solutions for ALS patients.
Exploring NurOwn's Potential
The NurOwn® platform involves autologous MSC-NTF cells, which present an innovative therapeutic approach focused on crucial pathways involved in neurodegenerative diseases. Unique to each individual with ALS, these cells are meticulously harvested and manufactured to secrete neurotrophic factors designed to target the specific neural deterioration caused by ALS.
Commitment to Research and Development
BrainStorm's dedication to ALS research has paved the way for advancements documented in numerous peer-reviewed journals. The NurOwn clinical program has provided vital insights into the complexities of ALS, pinpointing disease progression and informing treatment strategies. The company encourages a deep and rigorous analysis of collected datasets, covering several critical biomarkers observed across various phases of its clinical trials, especially during the Phase 3 analysis.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a frontrunner in developing autologous adult stem cell therapies targeted at severe neurodegenerative diseases. The company's exclusive worldwide licensing agreement secures its rights to develop and market the NurOwn® technology platform for producing autologous MSC-NTF cells, which have already earned Orphan Drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for ALS treatment.
Frequently Asked Questions
What are the upcoming presentations at the NEALS meeting?
BrainStorm will present two abstracts discussing the long-term benefits of Debamestrocel in ALS and an overview of the Phase 3b clinical trial.
Who is the lead author for the presentations?
Bob Dagher, MD, is the lead author for both presentations associated with NurOwn.
What is the purpose of the NurOwn technology platform?
NurOwn focuses on utilizing autologous MSC-NTF cells to develop treatments targeting neurodegenerative disease pathways, specifically in ALS.
How does BrainStorm demonstrate its commitment to ALS research?
BrainStorm supports ALS research through extensive clinical studies published in peer-reviewed journals and active participation in scientific meetings.
What is the significance of the upcoming Phase 3b trial?
The Phase 3b clinical trial aims to provide definitive evidence of NurOwn's efficacy, enhancing treatment options for early-stage ALS patients.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- US Stocks Show Mixed Performance Amid Jobs Data Anticipation
- Harris Advocates for Stronger Immigration Measures and Reform
- OpenAI Plans Price Increase for ChatGPT Subscription Service
- Hurricane Helene's Aftermath: A Battleground of Recovery Efforts
- Intel's Latest Rumors: What Investors Should Know Today
- Exploring China's Nature Reserve Network and Its Impact
- Learnologyworld Launches New Domain and Strategic Partnerships
- Unresolved Wage Negotiations: IAM and Boeing in Dispute
- Federal Reserve Signals Possible Interest Rate Changes Ahead
- ZYUS Life Sciences Secures Unsecured Loan for Growth Initiatives
Recent Articles
- SunHydrogen Joins Forces in Texas to Innovate Hydrogen Production
- Zuora Introduces Advanced Usage Pricing Features for SaaS Growth
- Omnicom Media Group Achieves Historic Business Growth in H1 2024
- KBR Secures $113 Million Contract to Transform Digital Engineering
- Leadership Evolution at Appcast: A New Era Begins
- Geotab Expands Telemetry Solutions with Volkswagen Partnership
- Ledger Investing Secures $100 Million in Innovative Reinsurance
- Grammarly Welcomes New Leaders: Enhancing Innovation & Growth
- The Second City Celebrates 65 Years with Unique Art Contest
- Marriott and Sands China to Launch Luxury Hotel in Macao
- PIM Brands Creates New Leadership Roles to Fuel Growth
- Geotab Forms Strategic Alliance with Volkswagen Group to Innovate Fleet Management
- Kia America Enhances EV Charging Accessibility with NACS Adaptors
- TotalEnergies Expands LNG Supply Through Strategic Agreement
- Nuvve Pioneers Electric School Bus Initiative with Groundbreaking Technology
- Contentstack Innovates Headless CMS with Visual Builder Tools
- Ledger Investing Secures Major Funding with New Casualty Sidecar
- Kingswood U.S. Strengthens Network with Eudaimonia Advisors
- Choreo's Charitable Contributions Impacting Communities Nationwide
- Larceny Bourbon Unveils Exciting Campaign to Inspire Adventure
- Halloween Horror Unwrapped: White Castle's Spooktacular Deals
- Jacqueline Heard Joins Sollum Technologies' Board of Directors
- Lilly's Kisunla Achieves Milestone in Alzheimer's Treatment
- KBR Secures $113 Million Contract for Future Tankers Development
- Squarespace Launches Refresh 2024 to Empower Entrepreneurs
- Polar Semiconductor Secures $123 Million Grant for Growth
- Piper Sandler Boosts Salesforce Rating Amid Positive Trends
- BMO Upgrades Ryan Specialty Group Amidst E&S Market Growth
- Raymond James Encourages Investors with Bullish DoorDash Outlook
- TripAdvisor Faces Market Challenges: Insights and Future Outlook
- Tesla's Robotaxi Reveal Could Boost Stock Valuation Significantly
- Middlefield Canadian Income PCC Sees Major Shareholder Activity
- Key Insights on CrowdStrike Holdings, Inc. Lawsuit for Investors
- Indivior PLC Faces Class Action Lawsuit Over Securities Fraud
- Investors Urged to Join Class Action Against Lululemon Athletica
- DXC Technology Under Legal Scrutiny: What Investors Should Know
- Maison Solutions Sees Impressive Stock Surge After Earnings
- Legal Action Against Ford Motor Company: Shareholder Rights Matter
- Important Update for Shareholders of Sage Therapeutics, Inc.
- Bank of Japan's Cautious Approach to Interest Rates Explained
- Sprinklr, Inc. Investors Can Take Action in Recent Class Action
- Generations Bancorp NY Set to Voluntarily Leave Nasdaq
- Class Action Lawsuit Against DexCom: What Investors Need to Know
- Endava plc (DAVA) Class Action: Protecting Investor Rights
- Arbor Realty Trust Shareholders Encouraged to Join Class Action
- Agenus Inc. Investors Urged to Join Class Action Lawsuit
- Investors Urged to Act in Five Below Fraud Class Action
- Verve Therapeutics Faces Class Action Lawsuit: What Investors Should Know
- Levi & Korsinsky Files Class Action for STMicroelectronics Investors
- Join the Fight: Class Action for Moderna, Inc. (MRNA) Investors